相关实验视频

Updated: Jun 18, 2025

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Published on: January 26, 2024

银化物Rg1抑制多发性骨髓瘤,并通过AMPK-mTOR途径克服博特佐米布耐药性

Li Lin¹, Dong Chen¹, Shuangyue Li¹

¹Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.

|July 29, 2024

概括

银化物Rg1通过AMPK-mTOR途径增强自,抑制多发性骨髓瘤 (MM) 的生长,并克服博特佐米布 (BTZ) 耐药性. Rg1显示为MM患者的辅助疗法有前途.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

多发性骨髓瘤 (MM) 呈现对博尔特佐米布 (BTZ) 的耐药性,这给临床提出了挑战.
氏体具有抗瘤特性,但Rg1在MM中的作用仍然未被探索.

研究的目的:

研究Rg1对MM生长的抑制作用.
评估Rg1降低MM中BTZ抗性的能力.
阐明Rg1作用的基本机制.

主要方法:

构建了一个抗BTZ的MM细胞系 (RPMI8226R).
建立了一个小鼠瘤载体模型.
评估了细胞增殖 (MTT测定),细胞灭亡 (流细胞计) 和自标志物 (LC3免疫光).
分析了蛋白质表达 (西方斑) 和瘤组织特征 (免疫组织化学).

主要成果:

在体外,Rg1抑制了MM细胞的增殖,促进了细胞灭绝,并增强了自.
Rg1增加了RPMI8226R细胞对BTZ的敏感性.
在小鼠中,Rg1阻碍了MM瘤的发展,减少了增殖和增加了亡.
Rg1的抗MM作用与AMPK-mTOR通路有关,诱导自以克服药物耐药性.

结论:

Rg1表现出显著的抗MM活性,并可以克服BTZ抵抗.
Rg1的机制涉及通过AMPK-mTOR通路调节自.
Rg1是多发性骨髓瘤治疗的潜在辅助治疗剂.

关键词:

自自是一种自的过程.博尔特佐米比 (Bortezomib) 是一种可怕的药物.药物耐药性药物耐药性药物耐药性人参化物 Rg1 多发性骨髓瘤是一种多发性骨髓瘤.

更多相关视频

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...